CytomX Therapeutics, Inc. - Common Stock (CTMX)
Frequently Asked Questions About CytomX Therapeutics, Inc. - Common Stock (CTMX)
How can I find more information about CytomX Therapeutics?
More information about CytomX Therapeutics can be found on their official website, where they provide updates on clinical trials, press releases, and financial reports. Investors and the public can also access details through financial news outlets and industry analysis.
How does CytomX aim to differentiate its therapies from competitors?
CytomX aims to differentiate its therapies through its proprietary Probody™ technology, which is designed to enhance therapeutic targeting and reduce off-target effects, thereby potentially leading to improved safety and efficacy compared to conventional therapies.
How is CytomX funded?
CytomX Therapeutics has historically raised capital through a combination of public offerings, private placements, and strategic partnerships. The company’s funding has also been supported by various grants and collaborations with research institutions and pharmaceutical companies.
How many employees does CytomX have?
As of the latest available data, CytomX Therapeutics employs a dedicated team of scientists, researchers, and professionals in various roles to advance its drug development efforts. The company’s workforce is crucial to driving innovation and achieving its business goals.
Is CytomX publicly traded?
Yes, CytomX Therapeutics, Inc. is publicly traded on the NASDAQ stock exchange under the ticker symbol CTMX. The company went public to raise funds for further development of its innovative therapies.
What are CytomX's lead product candidates?
CytomX's lead product candidates include several Probody therapeutics currently undergoing clinical trials. One of the most notable is the Probody drug targeting PD-L1 for cancer treatment, which highlights the company’s innovative approach to immunotherapy.
What are the future prospects for CytomX?
CytomX Therapeutics is well-positioned for future growth, with a robust pipeline of innovative product candidates and ongoing clinical trials. The company's focus on Probody™ technology and strategic partnerships could lead to significant advancements in cancer treatment.
What are the potential risks of investing in CytomX?
Investing in CytomX Therapeutics, like any biotech company, carries inherent risks, including the uncertainty of clinical trial outcomes, regulatory approvals, and market acceptance of its drug candidates. Investors should consider these factors when evaluating the company's stock.
What does CytomX Therapeutics, Inc. do?
CytomX Therapeutics, Inc. is a biotechnology company that focuses on developing innovative cancer therapies. The company specializes in the use of Probody™ technology, which aims to create targeted therapeutics that can selectively activate in the tumor microenvironment, thereby minimizing damage to healthy tissues and enhancing treatment efficacy.
What is Probody™ technology?
Probody™ technology is CytomX’s proprietary platform that enables the design of conditionally activated therapeutics, known as Probody therapeutics. These molecules are engineered to remain inactive until they encounter specific proteases that are overexpressed in the tumor microenvironment, allowing for selective targeting of cancer cells.
What is the status of CytomX's clinical trials?
CytomX Therapeutics is actively involved in multiple clinical trials for its Probody therapeutics, evaluating their effectiveness in treating various types of cancers. The company regularly updates the status of these trials on its website and through press releases.
What is the vision and mission of CytomX?
The vision of CytomX Therapeutics is to redefine cancer treatment by making targeted, effective therapies available to patients. Its mission is to leverage innovative science to develop Probody therapeutic candidates that address unmet medical needs in oncology.
What partnerships or collaborations does CytomX have?
CytomX Therapeutics has formed several strategic partnerships to aid in the development of its product candidates. Collaborations with large pharmaceutical companies for joint research initiatives and co-development efforts are integral to advancing its pipeline.
What recent developments have been announced by CytomX?
CytomX Therapeutics frequently announces updates on its clinical trials, partnerships, and regulatory filings. Recent developments may include trial results, new collaborations, or advancements in its Probody™ technology.
What types of cancer does CytomX focus on?
CytomX Therapeutics focuses on a range of cancers, particularly those characterized by high unmet medical needs. Their pipeline includes therapies targeting solid tumors such as breast cancer, lung cancer, and colorectal cancer, among others.
When was CytomX Therapeutics, Inc. founded?
CytomX Therapeutics, Inc. was founded in 2010, with the goal of transforming the treatment landscape for cancer patients through innovative approaches to immunotherapy and targeted therapies.
Where is CytomX Therapeutics, Inc. headquartered?
CytomX Therapeutics, Inc. is headquartered in South San Francisco, California, a hub for biotechnology innovation and research, which allows the company to collaborate with various industry partners and academic institutions.
Who are the key members of CytomX's executive team?
CytomX's executive team is led by experienced professionals from the biotechnology and pharmaceutical industries. Key members include the CEO, Chief Financial Officer, and Chief Scientific Officer, each bringing a wealth of experience in drug development and commercialization.
Who comprises CytomX's board of directors?
CytomX's board of directors consists of experienced professionals in the fields of biotechnology, finance, and healthcare. The board plays a crucial role in guiding the strategic direction of the company and overseeing its management.
What is the current price of CytomX Therapeutics, Inc. - Common Stock?
The current price of CytomX Therapeutics, Inc. - Common Stock is 0.4315
When was CytomX Therapeutics, Inc. - Common Stock last traded?
The last trade of CytomX Therapeutics, Inc. - Common Stock was at 4:00 pm EDT on April 7th, 2025
What is the market capitalization of CytomX Therapeutics, Inc. - Common Stock?
The market capitalization of CytomX Therapeutics, Inc. - Common Stock is 28.81M
How many shares of CytomX Therapeutics, Inc. - Common Stock are outstanding?
CytomX Therapeutics, Inc. - Common Stock has 66.77M shares outstanding.